NCT06384235View on ClinicalTrials.gov

Phase II Clinical Study of LTC004 in Patients With mCRC

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

August 23, 2025

Study Completion Date

August 23, 2025

Conditions
Locally Advanced or Metastatic CRC
Interventions
DRUG

LTC004

LTC004,45μg/kg,IV,Day 1,Q3W;

All Listed Sponsors
lead

Letolab

INDUSTRY

NCT06384235 - Phase II Clinical Study of LTC004 in Patients With mCRC | Biotech Hunter | Biotech Hunter